Explore

Trendline Trendline
Oligonucleotide Manufacturers Shift to Cost-Effective High Production Methods Amid Rising Demand

Oligonucleotide Manufacturers Shift to Cost-Effective High Production Methods Amid Rising Demand

Oligonucleotide Manufacturers Shift to Cost-Effective High Production Methods Amid Rising Demand
Trendline Trendline
Turn Therapeutics Publishes Study on GX-03 for Inflammatory Skin Conditions

Turn Therapeutics Publishes Study on GX-03 for Inflammatory Skin Conditions

Turn Therapeutics Publishes Study on GX-03 for Inflammatory Skin Conditions
Trendline Trendline
Arrowhead Pharmaceuticals Reveals Positive Data on Plozasiran for Patients with Renal and Hepatic Impairments

Arrowhead Pharmaceuticals Reveals Positive Data on Plozasiran for Patients with Renal and Hepatic Impairments

Arrowhead Pharmaceuticals Reveals Positive Data on Plozasiran for Patients with Renal and Hepatic Impairments
Trendline Trendline
Crystalys Therapeutics Initiates Phase 2 Trial for Gout Treatment with Dotinurad

Crystalys Therapeutics Initiates Phase 2 Trial for Gout Treatment with Dotinurad

Crystalys Therapeutics Initiates Phase 2 Trial for Gout Treatment with Dotinurad
Trendline Trendline
Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies
Trendline Trendline
Kardigan Files for IPO to Fund Cardiovascular Drug Development

Kardigan Files for IPO to Fund Cardiovascular Drug Development

Kardigan Files for IPO to Fund Cardiovascular Drug Development
Trendline Trendline
InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies

InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies

InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies
Trendline Trendline
Crystalys Therapeutics Initiates Phase 2 Trial for Dotinurad in Gout Patients

Crystalys Therapeutics Initiates Phase 2 Trial for Dotinurad in Gout Patients

Crystalys Therapeutics Initiates Phase 2 Trial for Dotinurad in Gout Patients
Trendline Trendline
Marea Therapeutics to Present Phase 1 Study Results of MAR002 for Acromegaly at ENDO 2026

Marea Therapeutics to Present Phase 1 Study Results of MAR002 for Acromegaly at ENDO 2026

Marea Therapeutics to Present Phase 1 Study Results of MAR002 for Acromegaly at ENDO 2026
Trendline Trendline
Arrowhead Pharmaceuticals Presents Positive Data on Plozasiran for Cardiometabolic Conditions

Arrowhead Pharmaceuticals Presents Positive Data on Plozasiran for Cardiometabolic Conditions

Arrowhead Pharmaceuticals Presents Positive Data on Plozasiran for Cardiometabolic Conditions
Trendline Trendline
Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity

Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity

Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity
Trendline Trendline
Delphia Therapeutics Appoints David P. Kerstein as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein as Chief Medical Officer to Advance Cancer Therapies